Literature DB >> 29333532

Molecular Docking: From Lock and Key to Combination Lock.

Ashutosh Tripathi1, Vytas A Bankaitis1,2,3.   

Abstract

Accurate modeling of protein ligand binding is an important step in structure-based drug design, is a useful starting point for finding new lead compounds or drug candidates. The 'Lock and Key' concept of protein-ligand binding has dominated descriptions of these interactions, and has been effectively translated to computational molecular docking approaches. In turn, molecular docking can reveal key elements in protein-ligand interactions-thereby enabling design of potent small molecule inhibitors directed against specific targets. However, accurate predictions of binding pose and energetic remain challenging problems. The last decade has witnessed more sophisticated molecular docking approaches to modeling protein-ligand binding and energetics. However, the complexities that confront accurate modeling of binding phenomena remain formidable. Subtle recognition and discrimination patterns governed by three-dimensional features and microenvironments of the active site play vital roles in consolidating the key intermolecular interactions that mediates ligand binding. Herein, we briefly review contemporary approaches and suggest that future approaches treat protein-ligand docking problems in the context of a 'combination lock' system.

Entities:  

Keywords:  Binding energy; Cavity detection; Docking; Fragment-based design; Molecular recognition; Pharmacophore; Scoring; Structure-based Drug design; Virtual screening

Year:  2017        PMID: 29333532      PMCID: PMC5764188          DOI: 10.16966/2575-0305.106

Source DB:  PubMed          Journal:  J Mol Med Clin Appl        ISSN: 2575-0305


  79 in total

1.  A method for biomolecular structural recognition and docking allowing conformational flexibility.

Authors:  B Sandak; R Nussinov; H J Wolfson
Journal:  J Comput Biol       Date:  1998       Impact factor: 1.479

2.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins.

Authors:  Christopher W Murray; Marcel L Verdonk
Journal:  J Comput Aided Mol Des       Date:  2002-10       Impact factor: 3.686

3.  Complexity in modeling and understanding protonation states: computational titration of HIV-1-protease-inhibitor complexes.

Authors:  Ashutosh Tripathi; Micaela Fornabaio; Francesca Spyrakis; Andrea Mozzarelli; Pietro Cozzini; Glen E Kellogg
Journal:  Chem Biodivers       Date:  2007-11       Impact factor: 2.408

4.  Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces.

Authors:  Nicholas J Burgoyne; Richard M Jackson
Journal:  Bioinformatics       Date:  2006-03-07       Impact factor: 6.937

5.  Using active site mapping and receptor-based pharmacophore tools: prelude to docking and de novo/fragment-based ligand design.

Authors:  Ashutosh Tripathi; J Andrew Surface; Glen E Kellogg
Journal:  Methods Mol Biol       Date:  2011

6.  Machine learning in computational docking.

Authors:  Mohamed A Khamis; Walid Gomaa; Walaa F Ahmed
Journal:  Artif Intell Med       Date:  2015-02-16       Impact factor: 5.326

7.  Flexible ligand docking using a genetic algorithm.

Authors:  C M Oshiro; I D Kuntz; J S Dixon
Journal:  J Comput Aided Mol Des       Date:  1995-04       Impact factor: 3.686

8.  A novel and efficient tool for locating and characterizing protein cavities and binding sites.

Authors:  Ashutosh Tripathi; Glen E Kellogg
Journal:  Proteins       Date:  2010-03

9.  Incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery.

Authors:  Marcus Fischer; Ryan G Coleman; James S Fraser; Brian K Shoichet
Journal:  Nat Chem       Date:  2014-05-25       Impact factor: 24.427

10.  MS-DOCK: accurate multiple conformation generator and rigid docking protocol for multi-step virtual ligand screening.

Authors:  Nicolas Sauton; David Lagorce; Bruno O Villoutreix; Maria A Miteva
Journal:  BMC Bioinformatics       Date:  2008-04-10       Impact factor: 3.169

View more
  8 in total

1.  Inhibitory Activity of Flavonoids, Chrysoeriol and Luteolin-7-O-Glucopyranoside, on Soluble Epoxide Hydrolase from Capsicum chinense.

Authors:  Jang Hoon Kim; Chang Hyun Jin
Journal:  Biomolecules       Date:  2020-01-24

2.  Non-invasive photobiomodulation treatment in an Alzheimer Disease-like transgenic rat model.

Authors:  Luodan Yang; Chongyun Wu; Emily Parker; Yong Li; Yan Dong; Lorelei Tucker; Darrell W Brann; Hung Wen Lin; Quanguang Zhang
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

3.  Going Retro, Going Viral: Experiences and Lessons in Drug Discovery from COVID-19.

Authors:  Bing Wang; Dmitri Svetlov; Dylan Bartikofsky; Christiane E Wobus; Irina Artsimovitch
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

Review 4.  Therapeutic non-invasive brain treatments in Alzheimer's disease: recent advances and challenges.

Authors:  Chongyun Wu; Luoman Yang; Shu Feng; Ling Zhu; Luodan Yang; Timon Cheng-Yi Liu; Rui Duan
Journal:  Inflamm Regen       Date:  2022-10-03

5.  Quantum tunnelling in the context of SARS-CoV-2 infection.

Authors:  Betony Adams; Ilya Sinayskiy; Rienk van Grondelle; Francesco Petruccione
Journal:  Sci Rep       Date:  2022-10-08       Impact factor: 4.996

Review 6.  New Insights Into DNA Helicases as Druggable Targets for Cancer Therapy.

Authors:  Arindam Datta; Robert M Brosh
Journal:  Front Mol Biosci       Date:  2018-06-26

7.  Inhibitory Activity of Quercetin 3-O-Arabinofuranoside and 2-Oxopomolic Acid Derived from Malus domestica on Soluble Epoxide Hydrolase.

Authors:  In Sook Cho; Jang Hoon Kim; Yunjia Lin; Xiang Dong Su; Jong Seong Kang; Seo Young Yang; Young Ho Kim
Journal:  Molecules       Date:  2020-09-22       Impact factor: 4.411

Review 8.  In Silico Approaches to Identify Polyphenol Compounds as α-Glucosidase and α-Amylase Inhibitors against Type-II Diabetes.

Authors:  Jirawat Riyaphan; Dinh-Chuong Pham; Max K Leong; Ching-Feng Weng
Journal:  Biomolecules       Date:  2021-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.